In summary, apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity, especially in patients with good performance status. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.